ReviewEndocrine2026
Glucocorticoids: an enemy or a friend for the dermatologist? recommendations for proper use and safe discontinuation.
Review in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGlucocorticoids (GCs) are steroid hormones produced by the adrenal cortex with anti-inflammatory and immunoregulating effects, thus essential for the management of numerous inflammatory and autoimmune disorders, including a wide range of dermatological conditions. The aim of our review is to summarize current data about the indications for GCs in dermatology, present the dermatological and endocrinological adverse effects and summarize current recommendations about the proper use and safe discontinuation of GCs, creating a practical guide for dermatologists.
methodsA narrative review of the literature on PubMed/MEDLINE was conducted and included articles in English, published until July, 2026. A combination of the keywords "glucocorticoids", "dermatology", "adrenal insufficiency", "HPA axis", "adverse effects" and "monitoring" was used to identify relevant literature for this review, with emphasis on recent recommendations and guidelines. The reference lists of the selected publications were also reviewed.
resultsAlthough GCs are commonly prescribed medications in dermatology, their use is associated with numerous adverse effects, extending beyond the skin to multiple organ systems. However, some side effects, such as adrenal insufficiency and withdrawal syndrome, may even be life-threatening.
conclusionDue to the expanded use of GCs, careful prescription and safe discontinuation is required. For this reason, we have created a practical clinical guide, summarizing the relevant recommendations to ensure proper use of GCs as well as safe discontinuation of the treatment. Optimal GC use requires individualized and careful selection of potency, duration, and route of administration to prevent any side effects and ensure the best outcome for the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.